Cargando…
Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer
With recent advancements in a non-invasive approach to cancer diagnosis and surveillance, the term “liquid biopsy” has gained traction but is currently limited by technological challenges in identifying and isolating circulating tumor cells (CTCs), proteins, cell-free DNA (cfDNA), or other nucleic a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877686/ https://www.ncbi.nlm.nih.gov/pubmed/31803629 http://dx.doi.org/10.3389/fonc.2019.01266 |
_version_ | 1783473385029763072 |
---|---|
author | Satyal, Uttam Srivastava, Abhishek Abbosh, Philip H. |
author_facet | Satyal, Uttam Srivastava, Abhishek Abbosh, Philip H. |
author_sort | Satyal, Uttam |
collection | PubMed |
description | With recent advancements in a non-invasive approach to cancer diagnosis and surveillance, the term “liquid biopsy” has gained traction but is currently limited by technological challenges in identifying and isolating circulating tumor cells (CTCs), proteins, cell-free DNA (cfDNA), or other nucleic acids. Tumor tissue biopsy, especially in genitourinary (GU) system is sometimes inadequate and requires invasive surgical options, especially for upper tract urothelial cancer. Urine can prove to be “liquid gold” since it may be a more abundant source of tumor-derived material without the background noise; however, urine DNA (uDNA) may be associated with low mutant allele fraction (MAF). Molecular detection of mutations in uDNA requires a sensitive and accurate method of analysis that allows a high depth of sequencing while minimizing artifacts. Several sequencing approaches to address this hurdle using enhanced library preparation techniques such as Tagged amplicon deep sequencing (TAm-Seq), Safe-SeqS, FAST-SeqS, and CAPP-Seq approaches have been developed. Urine biopsy utilizing next-generation sequencing (NGS) can prove useful at all stages of urologic malignancy care, where urine can be collected to aid in clinical decision making through the identification of commonly known mutations, and potentially reduce or avoid all forms of invasive procedures. |
format | Online Article Text |
id | pubmed-6877686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68776862019-12-04 Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer Satyal, Uttam Srivastava, Abhishek Abbosh, Philip H. Front Oncol Oncology With recent advancements in a non-invasive approach to cancer diagnosis and surveillance, the term “liquid biopsy” has gained traction but is currently limited by technological challenges in identifying and isolating circulating tumor cells (CTCs), proteins, cell-free DNA (cfDNA), or other nucleic acids. Tumor tissue biopsy, especially in genitourinary (GU) system is sometimes inadequate and requires invasive surgical options, especially for upper tract urothelial cancer. Urine can prove to be “liquid gold” since it may be a more abundant source of tumor-derived material without the background noise; however, urine DNA (uDNA) may be associated with low mutant allele fraction (MAF). Molecular detection of mutations in uDNA requires a sensitive and accurate method of analysis that allows a high depth of sequencing while minimizing artifacts. Several sequencing approaches to address this hurdle using enhanced library preparation techniques such as Tagged amplicon deep sequencing (TAm-Seq), Safe-SeqS, FAST-SeqS, and CAPP-Seq approaches have been developed. Urine biopsy utilizing next-generation sequencing (NGS) can prove useful at all stages of urologic malignancy care, where urine can be collected to aid in clinical decision making through the identification of commonly known mutations, and potentially reduce or avoid all forms of invasive procedures. Frontiers Media S.A. 2019-11-19 /pmc/articles/PMC6877686/ /pubmed/31803629 http://dx.doi.org/10.3389/fonc.2019.01266 Text en Copyright © 2019 Satyal, Srivastava and Abbosh. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Satyal, Uttam Srivastava, Abhishek Abbosh, Philip H. Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer |
title | Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer |
title_full | Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer |
title_fullStr | Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer |
title_full_unstemmed | Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer |
title_short | Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer |
title_sort | urine biopsy—liquid gold for molecular detection and surveillance of bladder cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877686/ https://www.ncbi.nlm.nih.gov/pubmed/31803629 http://dx.doi.org/10.3389/fonc.2019.01266 |
work_keys_str_mv | AT satyaluttam urinebiopsyliquidgoldformoleculardetectionandsurveillanceofbladdercancer AT srivastavaabhishek urinebiopsyliquidgoldformoleculardetectionandsurveillanceofbladdercancer AT abboshphiliph urinebiopsyliquidgoldformoleculardetectionandsurveillanceofbladdercancer |